Would you offer adjuvant AI + abemaciclib to a post-menopausal, node + luminal A breast cancer that did not require chemotherapy per Oncotype, yet still met criteria per monarchE?
- monarchE included <1% Stage IA and < 5% patients with no chemotherapy.
Ex: 64 yo, ER/PR 95%, Ki67 20%, cT1c N0 but pT1c N1a at lumpectomy/SLN biopsy with Oncotype 16.
Answer from: Medical Oncologist at Academic Institution
I think it is reasonable to offer this patient adjuvant abemaciclib even though the benefit of chemotherapy is expected to be low or nil based on the 21-gene (Oncotype) recurrence score, since the overall risk of recurrence would be higher based on the anatomic stage. In fact, the RSClin scoring sys...
Sign in or Register to read more